NORCROSS, Ga., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3,...
BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics...
Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST Clinical validation of PRAME...
First Genetically Modified (TALEN®-edited) Iovance TIL Therapy with Inactivated PD-1 Expression SAN CARLOS, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) --...
PRESS RELEASE: 10 October 2022, 07:00 CEST Biocartis Initiates Commercialization in Europe of HepatoPredict (CE-IVD) Test for Liver Cancer PatientsHepatoPredict helps...
New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021ANDOVER, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE)...
WOBURN, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...
Gross Proceeds of $30.5 Million RaisedYAVNE, Israel, Oct. 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated...
AGOURA HILLS, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments...
ILUVIEN or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to...
YAVNE, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused...
-- Single agent Anti-PD1-IL-2 BiSKIT™ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine...
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting Data on chlormethine in both...
Physician-led network offering complimentary skin cancer screenings across its network of clinics throughout OctoberMAITLAND, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE)...
Funds will advance research into ELI-007 as a mutant BRAF-peptide vaccine and ELI-008 as a p53 hotspot mutation-peptide vaccine, with...
--The Company Highlights its Clinical Strategy for its Adenosine and iNKT Platforms-- --Clinical Development Goals are Focused on Producing Phase...
AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments...
Phase 2 ACTIVATE trials to advance globally in metastatic patients who have progressed on available therapiesBotensilimab, alone and in combination...
Patricia Carlos named Chief Regulatory, Quality, and Safety OfficerTodd Yancey, MD named Senior Global Clinical Development, Medical Affairs and Commercial...
- Presentation at ESMO 2022 by Collaborator, Bristol Myers Squibb -- BMS-986249 Phase 2 study ongoing - SOUTH SAN FRANCISCO,...